Revolution Medicines

Yahoo Finance • 3 days ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story

Yahoo Finance • 5 days ago

Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now?

Is RVMD a good stock to buy? We came across a bullish thesis on Revolution Medicines, Inc. on Two Natural Capital’s Substack. In this article, we will summarize the bulls’ thesis on RVMD. Revolution Medicines, Inc.'s share was trading at $... Full story

Yahoo Finance • 10 days ago

Moderna stands as the best performing large-cap healthcare stock YTD

[Heart Health Concept] Eoneren/E+ via Getty Images U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its defensive appeal. Below is a list of the top 10 large-cap healthcare... Full story

Yahoo Finance • 12 days ago

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story

Yahoo Finance • 13 days ago

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

What happened According to an SEC filing dated February 17, 2026, DAFNA Capital Management LLC reduced its stake in iShares Biotechnology ETF(NASDAQ:IBB) by 34,405 shares during the fourth quarter of 2025. The fund’s quarter-end IBB posit... Full story

Yahoo Finance • 17 days ago

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine ora... Full story

Yahoo Finance • 19 days ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • 28 days ago

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story

Yahoo Finance • 29 days ago

Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca. Continue Reading... Full story

Yahoo Finance • 29 days ago

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story

Yahoo Finance • last month

Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best cancer stocks to invest in now. On February 26, Revolution Medicines, Inc. (NASDAQ:RVMD) CEO Mark A. Goldsmith reiterated that the company has made significant progress in develop... Full story

Yahoo Finance • last month

Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment?

Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time highs in Q4 2025, with the S&P 500 Index r... Full story

Yahoo Finance • last month

After-Hours Earnings Report for February 25, 2026 : NVDA, CRM, SNPS, SNOW, A, TCOM, VICI, FTAI, ZM, PSTG, RVMD, HEI

The following companies are expected to report earnings after hours on 02/25/2026. Visit our Earnings Calendar for a full list of expected earnings releases. NVIDIA Corporation (NVDA)is reporting for the quarter ending January 31, 2026... Full story

Yahoo Finance • last month

JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout

Revolution Medicines Inc. (NASDAQ:RVMD) is among the 15 Undervalued Momentum Stocks That Are Taking Off. JPMorgan added Overweight-rated Revolution Medicines Inc. (NASDAQ:RVMD) to its “Positive Catalyst Watch” list as per a February 17 re... Full story

Yahoo Finance • last month

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has Been Completed Phase I... Full story

Yahoo Finance • 3 months ago

All J.P. Morgan's top stock picks for 2026

[Countdown to 2026. Loading year from 2025 to 2026. New year start concept.] SmileStudioAP J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: * Strong Financial Health: Rob... Full story

Yahoo Finance • 3 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 4 months ago

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

Revolution Medicines, Inc. REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the firs... Full story

Yahoo Finance • 5 months ago

Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment

Earnings Call Insights: Revolution Medicines (RVMD) Q3 2025 MANAGEMENT VIEW * CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing treatment for patients with RAS-addicted cancers through... Full story

Yahoo Finance • 5 months ago

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinica... Full story